2015, Koopmans et al. 2019, Ilieva et al. 2017, Teppert et al. 2023). For malignant melanoma, a bispecific antibody therapy targeting both PD‐L1 and CSPG4 has been shown to restore the immune visibility of the tumour (Koopmans et al. 2019). In this work, we found that both PD‐L1 and CSPG4 were expressed in and on the EVs isolated from the serum of some of the EGFR‐mutated NSCLC patients. Therefore, it would be interesting to evaluate such bi‐specific PD–L1xCSPG4 antibody in the context of osimertinib in mutant EGFR‐driven NSCLC. The gene discussed is EGFR; the disease is melanoma.